169 related articles for article (PubMed ID: 12105139)
1. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Spencer CG; Gurney D; Blann AD; Beevers DG; Lip GY;
Hypertension; 2002 Jul; 40(1):61-6. PubMed ID: 12105139
[TBL] [Abstract][Full Text] [Related]
2. Effects of "newer" and "older" antihypertensive drugs on hemorrheological, platelet, and endothelial factors. A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Spencer CG; Felmeden DC; Blann AD; Lip GY
Am J Hypertens; 2007 Jun; 20(6):699-704. PubMed ID: 17531931
[TBL] [Abstract][Full Text] [Related]
3. Platelet and haemorheological markers in 'high risk' hypertensives are improved by tighter blood pressure control and cardiovascular risk management: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Spencer CG; Gurney D; Felmeden DC; Blann AD; Beevers DG; Lip GY
J Intern Med; 2004 Jan; 255(1):59-67. PubMed ID: 14687239
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial.
Varughese GI; Patel JV; Tomson J; Blann AD; Hughes EA; Lip GY
J Intern Med; 2007 Apr; 261(4):384-91. PubMed ID: 17391113
[TBL] [Abstract][Full Text] [Related]
5. Relationship of homocysteine to markers of platelet and endothelial activation in "high risk" hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Spencer CG; Martin SC; Felmeden DC; Blann AD; Beevers GD; Lip GY
Int J Cardiol; 2004 Apr; 94(2-3):293-300. PubMed ID: 15093996
[TBL] [Abstract][Full Text] [Related]
6. Haemorheological, platelet and endothelial indices in relation to global measures of cardiovascular risk in hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Spencer CG; Felmeden DC; Blann AD; Lip GY
J Intern Med; 2007 Jan; 261(1):82-90. PubMed ID: 17222171
[TBL] [Abstract][Full Text] [Related]
7. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy.
Lip GY; Blann AD; Jones AF; Lip PL; Beevers DG
Am J Cardiol; 1997 Dec; 80(12):1566-71. PubMed ID: 9416937
[TBL] [Abstract][Full Text] [Related]
8. Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Nadar SK; Blann AD; Kamath S; Beevers DG; Lip GY
J Am Coll Cardiol; 2004 Jul; 44(2):415-22. PubMed ID: 15261941
[TBL] [Abstract][Full Text] [Related]
9. A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Felmeden DC; Blann AD; Spencer CG; Beevers DG; Lip GY
Blood Coagul Fibrinolysis; 2003 Jul; 14(5):425-31. PubMed ID: 12851527
[TBL] [Abstract][Full Text] [Related]
10. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report.
Lip GY; Blann AD; Zarifis J; Beevers M; Lip PL; Beevers DG
J Hypertens; 1995 Dec; 13(12 Pt 2):1674-8. PubMed ID: 8903631
[TBL] [Abstract][Full Text] [Related]
11. von Willebrand factor, fibrinogen, and soluble P-selectin levels after mitral valve replacement versus mitral valve repair.
Goldsmith IR; Blann AD; Patel RL; Lip GY
Am J Cardiol; 2000 May; 85(10):1218-22. PubMed ID: 10802004
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation.
Conway DS; Pearce LA; Chin BS; Hart RG; Lip GY
Circulation; 2003 Jul; 107(25):3141-5. PubMed ID: 12796127
[TBL] [Abstract][Full Text] [Related]
13. Haemorheological, endothelial and platelet function in subjects with hypertension: relationship to cardiovascular risk and influence of antihypertensive treatment.
Spencer CG; Beevers DG; Lip GY;
J Hum Hypertens; 2001 Aug; 15 Suppl 1():S39-42. PubMed ID: 11685908
[No Abstract] [Full Text] [Related]
14. Plasma indices of endothelial and platelet activation in Rheumatoid Disease: relationship to cardiovascular co-morbidity.
Bhatia GS; Sosin MD; Patel JV; Grindulis KA; Khattak FH; Davis RC; Lip GY
Int J Cardiol; 2009 May; 134(1):97-103. PubMed ID: 18501982
[TBL] [Abstract][Full Text] [Related]
15. A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension.
Lip GY; Edmunds E; Hee FL; Blann AD; Beevers DG
Am J Hypertens; 2001 Aug; 14(8 Pt 1):823-8. PubMed ID: 11497201
[TBL] [Abstract][Full Text] [Related]
16. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
Poulter NR; Dobson JE; Sever PS; Dahlöf B; Wedel H; Campbell NR;
J Am Coll Cardiol; 2009 Sep; 54(13):1154-61. PubMed ID: 19761936
[TBL] [Abstract][Full Text] [Related]
17. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)].
Nadar SK; Blann A; Beevers DG; Lip GY
J Intern Med; 2005 Oct; 258(4):336-43. PubMed ID: 16164572
[TBL] [Abstract][Full Text] [Related]
18. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function.
Li-Saw-Hee FL; Blann AD; Gurney D; Lip GY
Eur Heart J; 2001 Sep; 22(18):1741-7. PubMed ID: 11511124
[TBL] [Abstract][Full Text] [Related]
19. Does the Dundee Step Test predict outcome in treated hypertension? A sub-study protocol for the ASCOT trial. Anglo-Scandinavian Cardiac Outcome Trial.
Lim PO; Donnan PT; MacDonald TM
J Hum Hypertens; 2000 Jan; 14(1):75-8. PubMed ID: 10673735
[TBL] [Abstract][Full Text] [Related]
20. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy.
Gibbs CR; Blann AD; Watson RD; Lip GY
Circulation; 2001 Apr; 103(13):1746-51. PubMed ID: 11282905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
